Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
about
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experienceImmunotherapy of type 1 diabetes: where are we and where should we be going?Efforts to prevent and halt autoimmune beta cell destruction.Anti-thymocyte globulin (ATG) differentially depletes naïve and memory T cells and permits memory-type regulatory T cells in nonobese diabetic mice.Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?Current concepts on the pathogenesis of type 1 diabetes--considerations for attempts to prevent and reverse the disease.Breakdown in peripheral tolerance in type 1 diabetes in mice and humansT cells in the control of organ-specific autoimmunityDiabetic ketoacidosis at diagnosis influences complete remission after treatment with hematopoietic stem cell transplantation in adolescents with type 1 diabetesCurrent and future immunomodulation strategies to restore tolerance in autoimmune diseases.Combination of double negative T cells and anti-thymocyte serum reverses type 1 diabetes in NOD miceMechanistic basis of immunotherapies for type 1 diabetes mellitusImaging the Beta-cell mass: why and howAntithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2 year results of a randomised trial.Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action.Autologous stem cell transplantation for early type 1 diabetes mellitus.Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice.Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the futureStem cell therapy for type 1 diabetes mellitus: a review of recent clinical trialsHarnessing regulatory T cells for the therapy of lupus and other autoimmune diseases.Type 1 diabetes: etiology, immunology, and therapeutic strategies.Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes.Making progress: preserving beta cells in type 1 diabetes.Clinical immunologic interventions for the treatment of type 1 diabetes.Novel therapy for type 1 diabetes: autologous hematopoietic stem cell transplantation.Emerging immune therapies in type 1 diabetes and pancreatic islet transplantation.Cell-based interventions to halt autoimmunity in type 1 diabetes mellitus.Progress in immune-based therapies for type 1 diabetes.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Anti-TCRβ mAb in Combination With Neurogenin3 Gene Therapy Reverses Established Overt Type 1 Diabetes in Female NOD Mice.Up-regulation of fas and fasL pro-apoptotic genes expression in type 1 diabetes patients after autologous haematopoietic stem cell transplantation
P2860
Q26850621-1BFAF8C1-1E69-4BBF-BADA-0B0E9030CBF4Q33815506-E67C504D-23B6-47F1-BEBF-1EC6F3CF2EC6Q34077363-D927475A-C22B-4205-A252-BB14D40AC552Q34511576-08D54367-630F-4C09-A8AC-BE555F06C59EQ35116303-1EB2DDEB-7752-4E0D-AEAF-0666FE89A754Q35630698-F6B668A7-0A85-4BD4-9E82-04793AFDE12AQ35765731-B6180742-2B90-4A41-95B4-94B189E7E448Q35836118-09CF393C-1CF9-44A6-BE6B-D100412C16C0Q36047307-8A5B1303-061F-43A8-8882-11F13F6CF95DQ36506677-F837F3AB-9B3B-4D66-AE42-080FD218D35EQ36611514-EEFC3047-3B2F-40B7-B359-89A65AF04E5EQ36698793-6C2AE325-B793-43E5-8CD3-2A7CEA92F8FAQ36839324-AD75E0AE-ED18-423C-90D0-C9C5992F4EFCQ36908165-689F99EA-E560-4F70-844E-5DD085F35976Q36958333-A228CBF8-E95D-48CE-971F-FFCDEEF8EFA2Q37311060-61D68F9E-5B72-480B-B378-8EC5A23A5D8FQ37360439-395F8879-8689-4562-B572-00E6EE3C7415Q37364899-41939415-B910-454E-8037-CE6D62AB496FQ37402021-5B3AEBBB-52CB-4127-BC6A-99536DB0DBF0Q37773268-927F4307-8F9F-4CED-A646-616FF2EF2F0FQ37830198-9EC43E3C-B44C-4DA3-99C2-5FE9AD0CDC87Q37883029-39963A9C-15A3-4BA0-B646-218CBD9C82B9Q37972677-C2A9EB33-2D1B-4C1C-A496-00798E4BA0F8Q38036230-E95574B9-13A8-4677-9B11-E674C951FE28Q38063360-8281F8A9-06A9-4DDB-8C22-0AE908E8405DQ38063547-D397825A-7FE3-4216-81AB-195C3E08B741Q38071420-890A0CA8-3553-4D2D-9D2B-C9B134BB7A00Q38097920-1AD0F81D-C5DB-4065-ACCA-425C1527AAF5Q38385236-215E9C5C-831C-4A30-AED2-7569043B49BBQ45872786-172D1BF5-E2D8-47CD-86F1-DA2E0B024763Q56787009-CAC4B5AC-9004-496C-B1E8-6D8FA9D91C01
P2860
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@ast
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@en
type
label
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@ast
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@en
prefLabel
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@ast
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@en
P2093
P2860
P356
P1476
Polyclonal anti-T-cell therapy for type 1 diabetes mellitus of recent onset.
@en
P2093
Frantisek Saudek
Jelena Skibova
Ludmila Karasova
Peter Novota
Petr Boucek
Tereza Havrdova
P2860
P356
10.1900/RDS.2004.1.80
P577
2004-08-10T00:00:00Z